Subunit vaccines: Distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system

Journal of Pharmaceutical Sciences

Volumn 100, Issue 5, 2011, Pages 1856-1865

  Mcneil, Sarah E ^a   Rosenkrands, Ida ^b   Agger, Else Marie ^b   Andersen, Peter ^b   Perrie, Yvonne ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

Immunology; Liposomes; Protein delivery; Proteins; Subunit vaccines; Vaccine adjuvant; Vaccines

Indexed keywords

AG85B EARLY SECRETORY ANTIGENIC TARGET 6; CHOLESTEROL; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DISTEAROYLPHOSPHATIDYLCHOLINE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOMODULATING AGENT; LIPOSOME; QUATERNARY AMMONIUM DERIVATIVE; SUBUNIT VACCINE; TREHALOSE 6,6 DIBEHENATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; FEMALE; IMMUNE RESPONSE; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY;

EID: 79952211982     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22427     Document Type: Article

References (42)

1. Allison AC, Gregoriadis G. 1974. Liposomes as immunological adjuvants. Nature 252(5480):252-252.
2. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, Agger EM, Andersen P. 2005. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6'-dibehenate) - A novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta (BBA) - Biomembranes 1718(1-2):22-31.
3. Gupta RK, Siber GR. 1995. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 13(14):1263-1276.
4. Henriksen-Lacey M, Bramwell VW, Christensen D, Agger E-M, Andersen P, Perrie Y. 2010. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 142(2):180-186.
5. Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, Perrie Y. 2010. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J Control Release 145(2):102-108.
6. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. 2008. Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens. Int J Pharm 364(2):272-280.
7. Jain AK, Chalasani KB, Khar RK, Ahmed FJ, Diwan PV. 2007. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery. J Drug Target 15(6):417-427.
8. Davis D, Gregoriadis G. 1987. Liposomes as adjuvants with immunopurified tetanus toxoid: Influence of liposomal characteristics. Immunology 61(2):229-234.
9. Kahl LP, Scott CA, Lelchuk R, Gregoriadis G, Liew FY. 1989. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. J Immunol 142(12):4441-4449.
10. Brunel F, Darbouret A, Ronco J. 1999. Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Vaccine 17(17):2192-2203.
11. Christensen D, Korsholm KS, Rosenkrands I, LindenstrÃm T, Andersen P, Agger EM. 2007. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 6(5):785-796.
12. Perrie Y, Gregoriadis G. 2000. Liposome-entrapped plasmid DNA: characterisation studies. Biochim Biophys Acta 1475(2):125-132.
13. Zelphati O, Wang Y, Kitada S, Reed JC, Felgner PL, Corbeil J. 2001. Intracellular delivery of proteins with a new lipid-mediated delivery system. J Biol Chem 276(37):35103-35110.
14. May S, Harries D, Ben-Shaul A. 2000. The phase behavior of cationic lipid DNA complexes. Biophys J 78(4):1681-1697.
15. McNeil SE, Vangala A, Bramwell VW, Hanson PJ, Perrie Y. Lipoplexes formulation and optimisation: In vitro transfection studies reveal no correlation with in vivo vaccination studies. Curr Drug Deliv 7:175-187.
16. Zuidam NJ, Barenholz Y. 1998. Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery. Biochim Biophys Acta 1368:115-128.
17. Saenger M, Borle F, Heller M, Sigrist H. 1992. Light-induced coupling of aqueous-soluble proteins to liposomes formed from carbene-generating phospholipids. Bioconjug Chem 3(4):308-314.
18. Masek J, Bartheldyová E, Korvasová Z, Skrabalová M, Koudelka S, Kulich P, Kratochvílová I, Miller AD, Ledvina M, Raska M, Turánek J. Immobilization of histidine-tagged proteins on monodisperse metallochelation liposomes: Preparation and study of their structure. Anal Biochem 408(1):95-104.
19. Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. 1997. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 65(2):623-629.
20. Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. 2004. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 72(3):1608-1617.
21. Lemaire G, Tenu JP, Petit JF, Lederer E. 1986. Natural and synthetic trehalose diesters as immunomodulators. Med Res Rev 6(3):243-274.
22. Olds GR, Chedid L, Lederer E, Mahmoud AA. 1980. Induction of resistance to Schistosoma mansoni by natural cord factor and synthetic lower homologues. J Infect Dis 141(4):473-478.
23. Vangala A, Bramwell VW, McNeil S, Christensen D, Agger EM, Perrie Y. 2007. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release 119(1):102-110.
24. Vangala A, Kirby D, Rosenkrands I, Agger EM, Andersen P, Perrie Y. 2006. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: Characterisation, environmental scanning electron microscopy and immunisation studies in mice. J Pharm Pharmacol 58(6):787-799.
25. Saarinen-Savolainen P, Jarvinen T, Taipale H, Urtti A. 1997. Method for evaluating drug release from liposomes in sink conditions. Int J Pharm 159(1):27-33.
26. Mohammed AR, Weston N, Coombes AGA, Fitzgerald M, Perrie Y. 2004. Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. Int J Pharma 285(1-2):23-34.
27. Papahadjopoulos D, Jacobson K, Nir S, Isac T. 1973. Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim Biophys Acta 311(3):330-348.
28. Jonas A, Maine GT. 1979. Kinetics and mechanism of phosphatidylcholine and cholesterol exchange between single bilayer vesicles and bovine serum high-density lipoprotein. Biochemistry 18(9):1722-1728.
29. Semple SC, Chonn A, Cullis PR. 1996. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry 35(8):2521-2525.
30. Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao BR, Rambhau D. 2002. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci 251(2):360-365.
31. Bangham AD, Standish MM, Watkins JC. 1965. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13(1):238-252.
32. Perrie Y, Frederik PM, Gregoriadis G. 2001. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 19(23-24):3301-3310.
33. Tsuruta LR, Quintilio W, Costa MH, Carmona-Ribeiro AM. 1997. Interactions between cationic liposomes and an antigenic protein: the physical chemistry of the immunoadjuvant action. J Lipid Res 38(10):2003-2011.
34. Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, Geisler C, Andersen P. 2007. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121(2):216-226.
35. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. 2004. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72(10):6148-6150.
36. Langermans JA, Doherty TM, Vervenne RA, Van Der Laan T, Lyashchenko K, Greenwald R, Agger EM, Aagaard C, Weiler H, van Soolingen D, Dalemans W, Thomas AW, Andersen P. 2005. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23(21):2740-2750.
37. Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K, Nimmerjahn F, Agger EM, Stenger S, Andersen P, Ruland J, Brown GD, Wells C, Lang R. 2010. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 184(6):2756-2760.
38. Werninghaus K, Babiak A, Gross O, Holscher C, Dietrich H, Agger EM, Mages J, Mocsai A, Schoenen H, Finger K, Nimmerjahn F, Brown GD, Kirschning C, Heit A, Andersen P, Wagner H, Ruland J, Lang R. 2009. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med 206(1):89-97.
39. Dagouassat N, Robillard V, Haeuw J-F, Plotnicky-Gilquin H, Power UF, Corvaïa N, Nguyen T, Bonnefoy J-Y, Beck A. 2001. A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine. Vaccine 19(30):4143-4152.
40. Jeong JM, Chung YC, Hwang JH. 2002. Enhanced adjuvantic property of polymerized liposome as compared to a phospholipid liposome. J Biotechnol 94(3):255-263.
41. Mazumdar T, Anam K, Ali N. 2004. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens. J Parasitol 91(2):269-274.
42. Bhowmick S, Ravindran R, Ali N. 2008. Gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun 76(3):1003-1015.